I just watched that. Almost a bit scary as wasnt someone talking about other trials that had used viral vectors and have worsened the target condition or caused inflammation. Looking forward to the day pyc get on the news.
Surely their method would work here also as it seems to be trying to deliver similar cargo just different target? Macular degeneration is a big target group i would think.
Quick search reveals usa has 11 million with some form of the disease so big target group. I wonder if it would work better with our delivery platform?
Ann: Set To Announce Efficacy Results For Second Drug Program, page-13
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.15 |
Change
0.020(1.77%) |
Mkt cap ! $670.7M | |||
| Open | High | Low | Value | Volume |
| $1.15 | $1.18 | $1.11 | $172.3K | 151.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 592 | $1.15 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.16 | 4211 | 1 |
View Market Depth
| Last trade - 16.10pm 20/06/2025 (20 minute delay) ? |
| PYC (ASX) Chart |